Intellia Therapeutics, Inc. - Common Stock (NTLA)

Small-cap benchmark Russell 2000 ETF hits record high after Fed cuts rates, hinting at more cuts. Small caps rally 43% since tariff-driven selloff.

Intellia Therapeutics Inc (NASDAQ:NTLA) shares are soaring on Thursday after the company completed enrollment in its crucial Phase 3 HAELO trial and laid out its key development milestones.

Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.

These companies are reaching key milestones.

The global economy in 2025 is navigating a landscape profoundly reshaped by the escalating demands of Artificial Intelligence (AI) and transformative shifts in healthcare. While the burgeoning energy consumption of AI data centers is putting unprecedented strain on power grids and catalyzing a new wave of investment across traditional and

Intellia Therapeutics (NTLA) reported Q2 2025 revenue of $14.25M, beating estimates, with a narrower loss of $0.99 per share. Stock rose 2% pre-market amid strong clinical progress in CRISPR therapies.

Vinay Prasad exits FDA's biologics division following pressure over Sarepta's Elevidys approval and regulatory controversies.

Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO.

KalVista's Ekterly, backed by strong trial data, receives FDA approval as the first oral therapy for acute hereditary angioedema attacks in the US.

FDA launches review of trials that sent American DNA to China without full consent; NIH investigates impact of Biden-era exemption on federally funded research

Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.

The companies were already collaborating on a handful of cardiovascular-focused gene-editing treatments.

Ark Invest made significant trades in TSLA, TXG, NTLA, DDD, and ADPT. Purchase of TXG and NTLA from ARKG and ARKK funds, and sale of TSLA, DDD, and ADPT from various funds.

Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

The patient’s elevated levels of liver enzymes appear to be resolving without hospitalization or medical intervention, the company said.

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment remains on track across programs.